The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis

References

• Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996 Dec;42(6):697–705.
   PubMed Web of Science ®Google Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012 Aug;142(2):432–439.
   PubMed Web of Science ®Google Scholar
• Wang Z. Bronchiectasis: still a problem. Chin Med J (Engl). 2014;127(1):157–172.
   PubMed Web of Science ®Google Scholar
• Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010 Oct;138(4):944–949.
   PubMed Web of Science ®Google Scholar
• Sugianto TD, Chan H-K. Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opin Drug Deliv. 2016;13(1):7–22.
   PubMed Web of Science ®Google Scholar
• King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411–419.
   PubMedGoogle Scholar
• Pasteur MC, Bilton D, Hill AT. British thoracic society non-CF bronchiectasis guideline groupbritish Thoracic Society Guideline for non-CF Bronchiectasis. . Thorax. 2010 Jul;65(7):577.
   PubMed Web of Science ®Google Scholar
• King PT, Daviskas E. Pathogenesis and diagnosis of bronchiectasis. Breathe. 2010;6(4):342–351.
   Google Scholar
• McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–656.Sep 15
   PubMed Web of Science ®Google Scholar
• Tay GTP, Reid DW, Bell SC. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med. 2015 Apr;36(2):267–286.
   PubMed Web of Science ®Google Scholar
• Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015 Nov;12(11):1602–1611.
   PubMed Web of Science ®Google Scholar
• Wilson R, Sethi S, Anzueto A, et al. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013 Dec;67(6):497–515.
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(Sep):3.
   Google Scholar
• Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009 Oct;34(4):843–849.
   PubMed Web of Science ®Google Scholar
• McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016 Dec;71(12):1110–1118.
   PubMed Web of Science ®Google Scholar
• Martínez-García MÁ, Máiz L, Olveira C, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol. 2018 Feb; (54)2:79-87.
   Web of Science ®Google Scholar
• Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2003 Mar;2(1):29–34.
   PubMedGoogle Scholar
• Proesmans M, Balinska-Miskiewicz W, et al. Evaluating the. “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J. 2006;27(5):937–943.May
   PubMed Web of Science ®Google Scholar
• Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):Jun.
   Web of Science ®Google Scholar
• Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016 Apr;47(4):1113–1122.
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability? Chest. 2010 Jul;138(1):158–164.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.Mar 1
   PubMed Web of Science ®Google Scholar
• Cantón R, Máiz L, Escribano A, et al. Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients. Arch Bronconeumol. 2015 Mar;51(3):140–150.
   PubMed Web of Science ®Google Scholar
• Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009 May;54(5):658–670.
   PubMed Web of Science ®Google Scholar
• Muers MF. Overview of nebuliser treatment. Thorax. 1997 Apr;52(Suppl 2):S25–30.
   PubMedGoogle Scholar
• Kuhn RJ. Formulation of aerosolized therapeutics. Chest. 2001 Sep;120(3Suppl):94S–98S.
   PubMedGoogle Scholar
• Rose LM, Neale R. Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci Transl Med. 2010 Dec 22;2(63):63mr4.
   PubMed Web of Science ®Google Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014 Aug;44(2):382–393.
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):481–485.
   PubMed Web of Science ®Google Scholar
• Couch LA. Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest. 2001 Sep;120(3Suppl):114S–117S.
   PubMedGoogle Scholar
• Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005 Jan;39(1):39–44.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–982.Apr 15
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JRW, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–499.Feb 15
   PubMed Web of Science ®Google Scholar
• Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999 Jul;93(7):476–480.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013 Sep;68(9):812–817.
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013 May;41(5):1107–1115.
   PubMed Web of Science ®Google Scholar
• Hagerman JK, Knechtel SA, Klepser ME. Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert Opin Pharmacother. 2007 Mar;8(4):467–475.
   PubMed Web of Science ®Google Scholar
• Heijerman H, Westerman E, Conway S. Consensus working group Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2009 Sep;8(5):295–315.
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985 Oct;132(4):761–765.
   PubMed Web of Science ®Google Scholar
• Page RL, Klem P, Rogers C, et al. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005 Jan;39(6):1109–1113.
   PubMed Web of Science ®Google Scholar
• Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002 Sep;20(3):658–664.
   PubMed Web of Science ®Google Scholar
• Má M-G, De Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014 May;43(5):1357–1367.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665.Oct 1
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009 May;135(5):1223–1232.
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921–928.Nov 1
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163–171.Jul 13
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep;2(9):738–749.
   PubMed Web of Science ®Google Scholar
• Gurjar M. Colistin for lung infection: an update. J Intensive Care. 2015;3(1):3.
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005 May 1;40(9):1333–1341.
   PubMed Web of Science ®Google Scholar
• Conole D, Keating GM. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs. 2014 Mar;74(3):377–387.
   PubMed Web of Science ®Google Scholar
• Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J Infect. 2014 Jul;69(1):1–12.
   PubMed Web of Science ®Google Scholar
• Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007 Jul;37(7):495–498.
   PubMed Web of Science ®Google Scholar
• Dhar R, Anwar GA, Bourke SC, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax. 2010 Jun;65(6):553.
   PubMed Web of Science ®Google Scholar
• Tabernero Huguet E, Gil Alaña P, Alkiza Basañez R, et al. [Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection]. Rev Espanola Geriatr Gerontol. 2015 Jun;50(3):111–115.
   PubMedGoogle Scholar
• Berlana D, Llop JM, Manresa F, et al. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy. 2011 Feb;31(2):146–157.
   PubMed Web of Science ®Google Scholar
• Olveira C, Muñoz A, Domenech A. Nebulized therapy SEPAR year. . Arch Bronconeumol. 2014 Dec;50(12):535–545.
   PubMed Web of Science ®Google Scholar
• Coates AL, Green M, Leung K, et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol. 2008 Aug;43(8):753–759.
   PubMed Web of Science ®Google Scholar
• Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev. 2013 Apr;30(4):CD007639.
   Google Scholar
• Spencer S, Felix LM, Milan SJ, et al. Oral versus inhaled antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;27(3):CD012579.
   Google Scholar